Frontier Questions
5 frontier questions in mTOR biology — not gaps in the Atlas's corpus, but questions about how the pathway is being measured: whether activity is read as a level when it behaves as a pattern, whether its outputs separate, whether location decides substrate choice, and which human ageing phenotypes are actually reachable.
Does mTORC1 carry information in the pattern of its activity over time, not its average level?
Nearly every study measures mTOR activity the way you would read a thermometer once: a single number, from a single moment, usually right after the cell was given a sudden jolt of nutrients. But real cells never get a su…
Is mTORC1 one pathway or several separable outputs — and which of them carries ageing?
Most of the argument is about how hard to press the brake, and recently about which of the two brakes to press. Hardly anyone asks which of the things the brake controls actually needs slowing. And those things do come a…
Is mTOR signalling decided by where the complex is active, rather than by how much of it is active?
The lysosome is normally described as mTOR's parking space. Newer structural work describes it more like a workbench: what the enzyme can reach depends on how it is docked. If that is right, two cells with the same amoun…
Does the timing of mTOR inhibition have to match the body's own pulses — feeding, exercise, sleep?
Giving the drug once a week instead of daily is usually explained as a way to lower the dose and avoid side effects. But if the pathway cares about rhythm, the question is not how often you give it — it is whether the ga…
Which human ageing phenotypes are causally reversible by mTOR modulation — and is it the same mechanism in each tissue?
Asking whether a drug makes people live longer cannot be answered in any reasonable amount of time, and aiming at it has crowded out better questions. Ageing is not one thing: the immune system, muscle, metabolism and th…